🇺🇸 SRPT — Sarepta Therapeutics, Inc.

Salud Mantener
← Volver

Precio actual

17,82 USD

Máx. histórico

178,74

2145 días

Split 1:6 del 12/07/2012

Caída desde máximo

-90,03%

Rango 52 semanas

14,68 – 24,68

Variación hoy

+1,42%

Cierre anterior

17,57

Rango de hoy

17,52 – 18,77

Volumen hoy

2.596.193

Peor caída histórica

-98,17%

09/02/2000 → 18/12/2008

Recuperado en 3568 días

Volatilidad anualizada ⓘ

95,43%

Información
Nombre completo
Sarepta Therapeutics, Inc.
Divisa
USD
Mercado
NasdaqGS
Sector
Salud
Industria
Biotechnology
Empleados
835
PER ⓘ
—
Dividend yield
0,00% (puede no estar actualizado)
Precio objetivo analistas
21,64 USD (puede no estar actualizado)
Primera cotización
04/06/1997
Precio actualizado
hace 19 horas
Sobre la empresa

Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, siRNA platform, gene therapy, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 for the treatment of Duchenne in patients who have a confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of Duchenne in patients who have a confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of Duchenne in patients who have a confirmed mutation of the dystrophin gene that is amenable to exon 45 skipping; and ELEVIDYS, an AAV-based gene therapy, which is contraindicated in patients with any deletion in exon 8 and/or exon 9 in the Duchenne gene. The company also develops SRP-9003, a gene therapy program for the treatment of LGMD2E; SRP-1001 to selectively target and knockdown DUX4 using RNAi in Phase 1/2a clinical trials; and SRP-1003 for reduction of expression of the DMPK gene in Phase 1/2a clinical trials. It has collaboration and license agreements with F. Hoffman-La Roche Ltd; Arrowhead Pharmaceuticals, Inc.; University of Western Australia; Nationwide Children's Hospital; Hansa Biopharma; and Duke University. The company was incorporated in 1980 and is headquartered in Cambridge, Massachusetts.

Splits Registrados en el histórico de precios
Fecha Ratio
12/07/2012 1:6
Rentabilidad mensual
Evolución
Histórico día a día
Fecha Apertura Máximo Mínimo Cierre Variación Volatilidad día Volumen
13/07/2012 4,24 4,24 3,60 3,83 -7,26% 15,09% 120.300
12/07/2012 3,30 4,22 3,30 4,13 +4,29% 27,88% 154.900
11/07/2012 3,90 3,96 3,78 3,96 +4,76% 4,62% 11.883
10/07/2012 3,96 3,96 3,78 3,78 -1,56% 4,55% 87.333
09/07/2012 3,90 3,96 3,78 3,84 -1,54% 4,62% 91.750
06/07/2012 3,72 3,90 3,72 3,90 +6,56% 4,84% 55.000
05/07/2012 3,78 4,02 3,66 3,66 -3,17% 9,52% 123.800
03/07/2012 3,66 3,84 3,66 3,78 +3,28% 4,92% 60.067
02/07/2012 3,66 3,84 3,60 3,66 -3,17% 6,56% 191.717
29/06/2012 3,84 4,02 3,78 3,78 -1,56% 6,25% 87.333
28/06/2012 4,02 4,02 3,78 3,84 -4,48% 5,97% 67.350
27/06/2012 4,14 4,20 3,78 4,02 +3,08% 10,14% 77.900
26/06/2012 3,72 3,96 3,72 3,90 +6,56% 6,45% 140.967
25/06/2012 3,78 3,90 3,66 3,66 -4,69% 6,35% 195.717
22/06/2012 4,14 4,26 3,72 3,84 -5,88% 13,04% 3.288.583
21/06/2012 4,20 4,32 4,02 4,08 -1,45% 7,14% 143.350
20/06/2012 4,02 4,38 4,02 4,14 +2,99% 8,96% 77.067
19/06/2012 3,84 4,50 3,84 4,02 +0,00% 17,19% 206.917
18/06/2012 3,90 4,20 3,78 4,02 +1,52% 10,77% 128.767
15/06/2012 4,20 4,20 3,90 3,96 -5,71% 7,14% 170.667
14/06/2012 3,96 4,20 3,84 4,20 +6,06% 9,09% 90.200
13/06/2012 3,78 4,02 3,78 3,96 +4,76% 6,35% 75.333
12/06/2012 3,90 3,96 3,72 3,78 -1,56% 6,15% 120.217
11/06/2012 4,14 4,14 3,84 3,84 -7,25% 7,25% 80.450
08/06/2012 4,14 4,50 3,90 4,14 -1,43% 14,49% 53.267
07/06/2012 4,44 4,92 4,08 4,20 -4,11% 18,92% 104.583
06/06/2012 3,90 4,38 3,90 4,38 +12,31% 12,31% 115.333
05/06/2012 3,84 4,02 3,60 3,90 -1,52% 10,94% 105.400
04/06/2012 3,66 4,02 3,66 3,96 +6,45% 9,84% 77.600
01/06/2012 3,78 3,90 3,66 3,72 -4,62% 6,35% 97.583